Biochemotherapy vs chemotherapy alone
Tumour response · people with cutaneous melanoma
Biochemotherapy leads to higher tumour response compared with chemotherapy (high certainty).
1 finding from 1 review
- RR 1.36 [1.12, 1.66]770 participantsHigh
Findings
What do systematic reviews say?
23 questions · 30 findings · 4 reviews · Headline outcomes only
No studies found 1 · 3.3%GRADE not reported 0 · 0%Very low 6 · 20%Low 9 · 30%Moderate 6 · 20%High 8 · 26.7%
Polychemotherapy vs chemotherapy alone
Tumour response · people with cutaneous melanoma
Polychemotherapy probably leads to higher tumour response compared with chemotherapy (moderate certainty).
1 finding from 1 review
- RR 1.27 [1.02, 1.58]1885 participantsModerate
Chemotherapy vs chemotherapy alone
Tumour response · advanced gastric adenocarcinoma
Chemotherapy showed no clear difference in tumour response rate (non‐taxane monotherapy vs taxane monotherapy) compared with chemotherapy (low certainty).
2 findings from 1 review
- Salvage systemic therapy for advanced gastric and oesophago‐gastric junction adenocarcinoma 2020 · Cochrane Headline outcomes onlyRR 0.65 [0.34, 1.26]1 study · 179 participantsLow
- Salvage systemic therapy for advanced gastric and oesophago‐gastric junction adenocarcinoma 2020 · Cochrane Headline outcomes onlyRR 0.89 [0.48, 1.67]1 study · 107 participantsLow
Chemotherapy vs chemotherapy alone
Tumour response rate (taxane‐containing doublet therapy vs taxane monotherapy) · advanced gastric adenocarcinoma
It is very uncertain whether chemotherapy changes tumour response rate (taxane‐containing doublet therapy vs taxane… compared with chemotherapy (very low certainty).
1 finding from 1 review
- Salvage systemic therapy for advanced gastric and oesophago‐gastric junction adenocarcinoma 2020 · Cochrane Headline outcomes onlyRR 1.47 [0.56, 3.89]2 studies · 121 participantsVery low
Chemotherapy vs biological therapy
Tumour response · advanced gastric and oesophago‐gastric junction adenocarcinoma
Chemotherapy showed no clear difference in tumour response rate compared with biological therapy (low certainty).
1 finding from 1 review
- Salvage systemic therapy for advanced gastric and oesophago‐gastric junction adenocarcinoma 2020 · Cochrane Headline outcomes onlyRR 1.17 [0.72, 1.88]1 study · 395 participantsLow
Chemotherapy vs placebo, best supportive care (BSC) or no treatment
Tumour response · advanced gastric and oesophago‐gastric junction adenocarcinoma
Chemotherapy showed no clear difference in tumour response rate compared with placebo, best supportive care (BSC) or no treatment (low certainty).
1 finding from 1 review
- Salvage systemic therapy for advanced gastric and oesophago‐gastric junction adenocarcinoma 2020 · Cochrane Headline outcomes onlyRR 2.17 [0.63, 7.48]1 study · 435 participantsLow
Chemotherapy vs best supportive care
Tumour response · people with metastatic CRC
The review found no eligible studies for this question.
1 finding from 1 review
- Second‐line systemic therapy for metastatic colorectal cancer 2017 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
Anti‐angiogenic drugs plus chemotherapy vs chemotherapy alone
Tumour response · people with cutaneous melanoma
Anti‐angiogenic drugs plus chemotherapy showed no clear difference in tumour response compared with chemotherapy (moderate certainty).
1 finding from 1 review
- RR 1.71 [0.96, 3.03]324 participantsModerate
Bevacizumab plus chemotherapy vs chemotherapy alone
Tumour response · people with metastatic CRC
Chemotherapy + bevacizumab leads to higher overall tumour response compared with chemotherapy (high certainty).
1 finding from 1 review
- Second‐line systemic therapy for metastatic colorectal cancer 2017 · Cochrane Headline outcomes onlyRR 1.72 [1.23, 2.43]4 studies · 1723 participantsHigh
Anti‐CTLA4 monoclonal antibodies plus chemotherapy vs chemotherapy alone
Tumour response · people with cutaneous melanoma
Anti‐CTLA4 monoclonal antibodies plus chemotherapy showed no clear difference in tumour response compared with chemotherapy (moderate certainty).
1 finding from 1 review
- RR 1.28 [0.92, 1.77]1157 participantsModerate
Modern chemotherapy regimens vs 5‐flourouracil
Tumour response · people with metastatic CRC
Modern chemotherapy regimens leads to higher overall tumour response compared with 5‐flourouracil (high certainty).
1 finding from 1 review
- Second‐line systemic therapy for metastatic colorectal cancer 2017 · Cochrane Headline outcomes onlyRR 2.96 [1.66, 5.27]3 studies · 866 participantsHigh
Combination vs single‐agent chemotherapy
Tumour response · people with advanced gastric cancer
Combination leads to higher tumour response compared with single‐agent chemotherapy (high certainty).
1 finding from 1 review
- OR 2.3 [1.94, 2.72]18 studies · 2833 participantsHigh
BRAF inhibitors vs chemotherapy alone
Tumour response · people with cutaneous melanoma
BRAF inhibitors leads to higher tumour response compared with chemotherapy (high certainty).
1 finding from 1 review
- RR 6.78 [4.84, 9.49]925 participantsHigh
MEK inhibitors vs chemotherapy alone
Tumour response · people with cutaneous melanoma
MEK inhibitors leads to higher tumour response compared with chemotherapy (high certainty).
1 finding from 1 review
- RR 2.01 [1.35, 2.99]496 participantsHigh
Anti‐PD1 monoclonal antibodies vs chemotherapy alone
Tumour response · people with cutaneous melanoma
Anti‐PD1 monoclonal antibodies leads to higher tumour response compared with chemotherapy (high certainty).
1 finding from 1 review
- RR 3.42 [2.38, 4.92]1367 participantsHigh
Chemmotherapy combined with biological therapy vs chemotherapy alone
Tumour response · advanced gastric and oesophago‐gastric junction adenocarcinoma
It is very uncertain whether chemmotherapy combined with biological therapy changes tumour response rate compared with chemotherapy (very low certainty).
1 finding from 1 review
- Salvage systemic therapy for advanced gastric and oesophago‐gastric junction adenocarcinoma 2020 · Cochrane Headline outcomes onlyRR 1.35 [0.99, 1.85]6 studies · 2404 participantsVery low
Irinotecan vs non‐irinotecan‐containing regimens
Tumour response · people with advanced gastric cancer
Irinotecan may leads to higher tumour response compared with non‐irinotecan‐containing regimens (low certainty).
4 findings from 1 review
- OR 1.72 [1.24, 2.4]10 studies · 1266 participantsLow
- OR 1.53 [0.93, 2.5]6 studies · 756 participantsLow
- OR 2.18 [1.25, 3.8]3 studies · 345 participantsLow
Show 1 more finding
- OR 1.87 [0.89, 3.91]2 studies · 165 participantsVery low
Docetaxel vs non‐docetaxel‐containing regimens
Tumour response · people with advanced gastric cancer
Docetaxel probably leads to higher tumour response compared with non‐docetaxel‐containing regimens (moderate certainty).
4 findings from 1 review
- OR 1.37 [1.03, 1.83]9 studies · 1820 participantsModerate
- OR 1.03 [0.71, 1.5]4 studies · 525 participantsModerate
- OR 1.83 [1.45, 2.32]4 studies · 1235 participantsHigh
Show 1 more finding
- OR 0.33 [0.12, 0.96]1 study · 60 participantsVery low
Capecitabine vs 5‐FU‐containing regimens
Tumour response · people with advanced gastric cancer
It is very uncertain whether capecitabine changes tumour response compared with 5‐FU‐containing regimens (very low certainty).
1 finding from 1 review
- OR 0.85 [0.4, 1.79]4 studies · 636 participantsVery low
Oxaliplatin vs the same regimen including cisplatin
Tumour response · people with advanced gastric cancer
Oxaliplatin probably leads to higher tumour response compared with the same regimen including cisplatin (moderate certainty).
1 finding from 1 review
- OR 1.38 [1.08, 1.76]5 studies · 1081 participantsModerate